CytomX Therapeutics, Inc. has grown revenue −39% a year over three years and −20% a year over five. Revenue growth, 3-year annual rate: −39% (Biotechnology median +17%). Revenue growth, 5-year rate: −20%, growth has slowed since the five-year average. Years of annual history on file: 13, FY2013 to FY2025, as filed.

CTMXCytomX Therapeutics, Inc.

Healthcare

$2.46-26% 1Y

$2.46

$2.4652 weeks$6.75

Latest close: a new 52-week lowOct 8, 2026what changed →

Is it growing?

Watch

Growth is fading: revenue shrinking (−87% year on year) and operating margin narrowing (−1610.6 points).

2 to watch, 1 without data

Revenue trend−87% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −20% a year.

Margin direction−1610.6 points operating

Trailing-twelve-month operating margin, -1586.6% now against 24.1% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is CTMX growing?

CytomX Therapeutics, Inc. has grown revenue −39% a year over three years and −20% a year over five.

−39%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −20%
Revenue growth, 5-year rate · −39% over three · growth has slowed since the five-year average
Years of annual history on file: 13
Years of annual history on file · FY2013 to FY2025, as filed

Details›